CORRECTED-INSIGHT-US benefits manager baulks after Novartis values gene therapy at $4-5 mln
November 23, 2018 at 11:11 AM EST
* At $4-5 mln, SMA treatment would be one of industry's costliest
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|